Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Veterinary technicians are crucial to pet healthcare and the demand and necessity for this key role has continued to increase post pet boom. However, 47% of pet owners are unaware of how impactful a ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

Other promising candidates in Exelixis’ pipeline zanzalintinib, a next-generation oral TKI and XL309. In the first half of 2025, Exelixis intends to initiate a phase III study, STELLAR-311, to ...

Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess casdatifan plus volrustomig for renal ...